肝素诱导的血小板减少症诊治进展
Progress in the Diagnosis of Heparin-Induced Thrombocytopenia
DOI: 10.12677/ACM.2020.1011391, PDF,   
作者: 齐 微, 王 悦, 王 哲, 夜雪敏：延安大学医学院，陕西 延安；邢延芳*：延安大学附属东关分院检验科，陕西 延安
关键词: 肝素；血小板减少；HIT抗体；血栓栓塞；抗凝药；Heparin； Thrombocytopenia； HIT Antibody； Thromboembolism； Anticoagulant
摘要: 肝素诱导的血小板减少症(Heparin-induced thrombocytopenia, HIT)是使用肝素抗凝治疗后出现的一种严重不良反应，可导致血栓形成，造成器官或肢体血栓栓塞，严重者危及生命。由于HIT临床过程隐匿，且症状不典型，易造成误诊和漏诊。然而，国内对HIT的认知和诊疗严重不足。本文通过检索HIT相关文献，对HIT的发病机制、临床表现、诊断及治疗作一综述，旨在为临床医生早期诊断、鉴别和治疗提供参考。
Abstract: Heparin-induced thrombocytopenia (HIT) is a common complication of heparin anticoagulant therapy, which can lead to thromboembolism in organs or limbs, and serious life-threatening. Due to the clinical process of HIT is concealed and the symptoms are not typical, it is easy to cause missed and delayed diagnosis. However, there are serious insufficiency in the cognition and diagnosis of HIT in domestic. This article intends to describe the latest developments in the clinical manifestations, laboratory tests and diagnosis, in order to guide clinicians to early identify and diagnose of the syndrome.
文章引用：齐微, 王悦, 王哲, 夜雪敏, 邢延芳. 肝素诱导的血小板减少症诊治进展[J]. 临床医学进展, 2020, 10(11): 2582-2587. https://doi.org/10.12677/ACM.2020.1011391

参考文献

[1] 武东, 汪晓娟, 汪小五, 等. 104例住院患者药源性血小板减少症不良反应报告分析[J]. 中国医院药学杂志, 2019, 39(17): 1766-1771.
[2] Warkentin, T.E., Sheppard, J.A., Horsewood, P., et al. (2000) Impact of the Patient Population on the Risk for Heparin-induced Thrombocytopenia. Blood, 96, 1703-1708. [Google Scholar] [CrossRef] 
[3] Shen, Y.-M., Heather, W. and Stephen, B. (2018) Evaluating Thrombocytopenia during Heparin Therapy. JAMA, 319, 497. [Google Scholar] [CrossRef] [PubMed]
[4] 郑永威, 袁榴娣. 肝素诱导性血小板减少症的研究进展[J]. 东南大学学报(医学版), 2014, 33(6): 815-819.
[5] 雷迁, 陈雷. 肝素/血小板因子4抗体与肝素诱导的血小板减少症[J]. 中国实验血液学杂志, 2008(2): 457-460.
[6] Rauova, L., Arepally, G., Poncz, M., et al. (2018) Molecular and Cellular Pathogenesis of Heparin-Induced Thrombocytopenia (HIT). Autoimmunity Reviews, 17, 1046-1052. [Google Scholar] [CrossRef] [PubMed]
[7] 曹磊, 谭颖, 吕继成, 等. 肝素诱导的血小板减少症[J]. 中国血液净化, 2009, 8(3): 163-166.
[8] 范庆坤, 张真路. 如何面对肝素诱导血小板减少症诊断的困惑[J]. 中华检验医学杂志, 2019, 42(4): 227-231.
[9] 门剑龙, 任静. 肝素诱导的血小板减少症的实验室诊断进展[J]. 中华检验医学杂志, 2016, 39(10): 795-800.
[10] Warkentin, T.E. (2012) HITlights: A Career Perspective on Heparin-Induced Thrombocytopenia. American Journal of Hematology, 87, S92-S99. [Google Scholar] [CrossRef] [PubMed]
[11] Cohen, R.A., Castellano, M. and Garcia, C.A. (2012) Heparin Induced Thrombocytopenia: Case Presentation and Review. Journal of Clinical Medicine Research, 4, 68-72. [Google Scholar] [CrossRef] [PubMed]
[12] Dasararaju, R., Singh, N. and Mehta, A. (2013) Heparin Induced Thrombocytopenia: Review. Expert Review of Hematology, 6, 419-428. [Google Scholar] [CrossRef] [PubMed]
[13] Cuker, A., Rux, A.H., Hinds, J.L., et al. (2013) Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. Blood, 121, 3727-3732. [Google Scholar] [CrossRef] [PubMed]
[14] Cuker, A., Gimotty, P.A., Crowther, M.A., et al. (2012) Predictive Value of the 4Ts Scoring System for Heparin-Induced Thrombocytopenia: A Systematic Review and Meta-Analysis. Blood, 120, 4160-4167. [Google Scholar] [CrossRef] [PubMed]
[15] Joseph, L., Gomes, M.P.V., Al, S.F., et al. (2015) External Validation of the HIT Expert Probability (HEP) Score. Thrombosis and Haemostasis, 113, 633-640. [Google Scholar] [CrossRef] 
[16] Pishko, A.M., Fardin, S., Lefler, D.S., et al. (2018) Prospective Comparison of the Hep Score and 4ts Score for the Diagnosis of Heparin-Induced Thrombocytopenia. Blood Advances, 2, 3155-3162. [Google Scholar] [CrossRef] [PubMed]
[17] Lillo-Le, L.A., Boutouyrie, P., Alhenc-Gelas, M., et al. (2004) Diagnostic Score for Heparin-Induced Thrombocytopenia after Cardiopulmonary Bypass. Journal of Thrombosis and Haemostasis, 2, 1882-1888. [Google Scholar] [CrossRef] [PubMed]
[18] Compton, F.B., Alrabeh, R., Nguyen, L.Q., et al. (2018) Pifa Pluss P4 Assay for Screening of Heparin-Induced Throm- bocytopenia. Laboratory Medicine, 50, 73-77. [Google Scholar] [CrossRef] [PubMed]
[19] 周福硕, 黄凌瑾, 王锷, 等. 心脏手术患者围术期肝素诱导的血小板减少症[J]. 中南大学学报(医学版), 2015, 40(7): 790-796.
[20] 中国医师协会心血管内科医师分会血栓防治专业委员会与编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017) [J]. 中华医学杂志, 2018, 98(6): 408-417.
[21] 于坤, 梁碧霞, 刘明政, 等. 肝素诱导的血小板减少症患者心脏外科手术期间抗凝治疗[J]. 中国体外循环杂志, 2018, 16(5): 297-301.
[22] 张明哲, 姚允泰, 李立环. 心脏手术患者肝素诱导血小板减少症[J]. 中国体外循环杂志, 2018, 16(5): 293-296, 311.
[23] 冯湧. 新一代抗凝血药阿加曲班的临床应用进展[J]. 医学信息, 2018, 31(2): 43-45.
[24] Nutescu, E.A., Shapiro, N.L. and Chevalier, A. (2007) New Anticoagulant Agents: Direct Thrombin Inhibitors. Cardiology Clinics, 26, 169-187. [Google Scholar] [CrossRef] [PubMed]
[25] Zhou, P., Yin, J.-X., Tao, H.-L., et al. (2020) Pathogenesis and Management of Heparin-Induced Thrombocytopenia and Thrombosis. Clinica Chimica Acta, 504, 73-80. [Google Scholar] [CrossRef] [PubMed]
[26] 伍雪峰, 金至赓, 赖斌, 刘惠亮. 急性冠脉综合征患者经皮冠状动脉介入术中比伐卢定的研究进展[J]. 中华灾害救援医学, 2017, 5(2): 101-105.
[27] 晋辉, 邱翠婷, 刘静, 等. 比较阿加曲班和比伐卢定在高出血风险且肝素诱导的血小板减少症-IgG抗体阳性的ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗中的抗凝疗效[J]. 中国循环杂志, 2019, 34(6): 545-551.
[28] Marc, S., Julia, S., Jan, B.-W., et al. (2017) Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. Journal of the American College of Cardiology, 70, 2636-2648. [Google Scholar] [CrossRef] [PubMed]
[29] Poudel, Ghimire, Dhital, et al. (2017) Spontaneous Hit Syndrome Post-Knee Replacement Surgery with Delayed Recovery of Thrombocytopenia: A Case Report and Literature Review. Platelets, 28, 614-620. [Google Scholar] [CrossRef] [PubMed]
[30] Tvito, A., Bakchoul, T., Rowe, J.M., et al. (2015) Severe and Persistent Heparin-Induced Thrombocytopenia Despite Fondaparinux Treatment. American Journal of Hematology, 90, 675-678. [Google Scholar] [CrossRef] [PubMed]
[31] Aryal, M.R., Gosain, R., Donato, A., et al. (2020) Effectiveness of Intravenous Immunoglobulin Use in Heparin-Induced Thrombocytopenia. Blood Coagulation & Fibrinolysis, 31, 287-292. [Google Scholar] [CrossRef] 

为你推荐